Results 271 to 280 of about 2,849,098 (354)

Fosfomycin combination therapy in high-risk paediatric patients with multidrug-resistant infections: a retrospective study. [PDF]

Eur J Pediatr
Denina M, Badiali L, Vitale R, Robasto F, Funiciello E, Silvestro E, Pruccoli G, Garazzino S.   +7 more
europepmc   +1 more source

Predicting Epileptogenic Tubers in Patients With Tuberous Sclerosis Complex Using a Fusion Model Integrating Lesion Network Mapping and Machine Learning

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Accurate localization of epileptogenic tubers (ETs) in patients with tuberous sclerosis complex (TSC) is essential but challenging, as these tubers lack distinct pathological or genetic markers to differentiate them from other cortical tubers.
Tinghong Liu, Qi Wang, Suhui Kuang, Dezhi Cao, Ping Ding, Shaohui Zhang, Haihua Wei, Zhirong Wei, Jinshan Xu, Xinyu Huang, Bing Liu, Shuli Liang   +11 more
wiley   +1 more source

Efimosfermin for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): Mechanism of Action, Clinical Development and Emerging Therapeutic Potential. [PDF]

Drug Des Devel Ther
Alamgir M, Sohal A, Kowdley KV.
europepmc   +1 more source

Life‐Threatening Bradycardia in Anti‐NMDA‐Receptor Encephalitis and a Novel Use for Permanent Pacing

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Pediatric anti‐NMDA receptor encephalitis (pNMDARE) is an autoantibody‐mediated disorder that can cause severe autonomic dysfunction, including symptomatic bradycardia and asystole. Dysautonomia can last for years, making it very challenging to manage.
Sarah Tucker, Abhijit Das, Andres Jimenez, Areeba Basit, Yike Jiang, Emily A. Smitherman, Heather Van Mater, Taylor Howard, Alexander J. Sandweiss, Kristen S. Fisher   +9 more
wiley   +1 more source

Antibody-Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions. [PDF]

MedComm (2020)
Cheng B, Gong L, Wang Z, Peng P, Xu K, Huang H, Wu P.   +6 more
europepmc   +1 more source

[Drug interactions in combination drug therapy].

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1993
openaire   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source

Targeted Therapies for Each Subtype of Breast Cancer. [PDF]

MedComm (2020)
Liu A, Peng P, Zhu Y, Fei Q, Liu W, Zhang S.   +5 more
europepmc   +1 more source

Editorial Comment: "Could We Maintain the Initial Efficacy of Triple Sequential Combination Therapies with Selexipag Against Progressive Deterioration Risk in Patients with Pulmonary Arterial Hypertension: Insights from a Single-Centre Study". [PDF]

Anatol J Cardiol
Badagliacca R, Tello K.
europepmc   +1 more source

Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity. [PDF]

Sci Adv
Meng H, Chang Q, Zhang Y, Ren J, Guo H, Yu L, Qian C, Jiang Y, Zhang L, Cheng W.   +9 more
europepmc   +1 more source